Jump to content

Denosumab therapy and risk for severe hypocalcemia

Paul Edwards

Recommended Posts

Denosumab (brand name Xgeva)  is associated with a rare but well-known risk for severe hypocalcemia (very low calcium in the blood stream).


The "New" Prostate Cancer InfoLink has an article about this risk which includes a very sensible warning:


"If your doctor advises you that you would be appropriately treated with denosumab for prevention of skeletal-related events associated with advanced forms of prostate cancer (particularly in men with metastatic disease on long-term androgen deprivation therapy), you need to be sure that your serum calcium and vitamin D levels are monitored prior to initiation of therapy."

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...